Affordable Access

deepdyve-link
Publisher Website

Chemotherapeutics of visceral leishmaniasis: present and future developments.

Authors
  • Sundar, Shyam1
  • Singh, Anup1
  • 1 Department of Medicine,Institute of Medical Sciences,Banaras Hindu University,Varanasi 221005,India. , (India)
Type
Published Article
Journal
Parasitology
Publication Date
Apr 01, 2018
Volume
145
Issue
4
Pages
481–489
Identifiers
DOI: 10.1017/S0031182017002116
PMID: 29215329
Source
Medline
Keywords
License
Unknown

Abstract

SUMMARYTreatment of Visceral Leishmaniasis (VL), a neglected tropical disease, is very challenging with few treatment options. Long duration of treatment and drug toxicity further limit the target of achieving VL elimination. Chemotherapy remains the treatment of choice. Single dose of liposomal amphotericin B (LAmB) and multidrug therapy (LAmB + miltefosine, LAmB + paromomycin (PM), or miltefosine + PM) are recommended treatment regimen for treatment of VL in Indian sub-continent. Combination therapy of pentavalent antimonials (Sbv) and PM in East Africa and LAmB in the Mediterranean region/South America remains the treatment of choice. Various drugs having anti-leishmania properties are in preclinical phase and need further development. An effective treatment and secondary prophylaxis of HIV-VL co-infection should be developed to decrease treatment failure and drug resistance.

Report this publication

Statistics

Seen <100 times